Key Takeaway: The article discusses Cognition Therapeutics' stance on third-party websites. It emphasizes that the company does not control or endorse the content found on these external sites and encourages users to review their terms and privacy policies. This reflects the company's commitment to transparency and user awareness.
Price reaction · baseline $1.84 (2024-04-18 close) · hit after-hours · clean, no other CGTX news in the window
day 0 close
0%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What does Cognition Therapeutics say about third-party websites?
Cognition Therapeutics states it does not control or endorse third-party content.
Why should users evaluate third-party site policies?
Users are encouraged to review terms and privacy policies as they may differ from Cognition's.